850429-62-8

Basic information

• Product Name: 2-TERT-BUTOXYCARBONYLAMINOTHIAZOLE-4-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 2-TERT-BUTOXYCARBONYLAMINOTHIAZOLE-4-CARBOXYLIC ACID METHYL ESTER;METHYL 2-(TERT-BUTOXYCARBONYLAMINO)THIAZOLE-4-CARBOXYLATE;METHYL 2-AMINO-1,3-THIAZOLE-4-CARBOXYLATE, N-BOC PROTECTED;METHYL 2-(BOC-AMINO)-4-THIAZOLECARBOXYLATE;METHYL 2-(BOC-AMINO)THIAZOLE-4-CARBOXYLATE;BOC-2-AMINO-4-THIAZOLE-CARBOXYLIC ACID METHYL ESTER;Methyl 2-amino-1,3-thiazole-4-carboxylate, N-BOC protected 98%;N-BOC-METHYL 2-AMINO-1,3-THIAZOLE-4-CARBOXYLATE
• CAS NO: 850429-62-8
• Molecular Formula: C10H14N2O4S
• Molecular Weight: 258.29
• Product Categories: blocks;Carboxes;Thiazoles
• Mol File: 850429-62-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 156-160
• Appearance: /
• Density: 1.297 g/cm³
• Refractive Index: 1.56
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-TERT-BUTOXYCARBONYLAMINOTHIAZOLE-4-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-TERT-BUTOXYCARBONYLAMINOTHIAZOLE-4-CARBOXYLIC ACID METHYL ESTER(850429-62-8)
• EPA Substance Registry System: 2-TERT-BUTOXYCARBONYLAMINOTHIAZOLE-4-CARBOXYLIC ACID METHYL ESTER(850429-62-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 850429-62-8(Hazardous Substances Data)

Usage

Uses

N-Boc Methyl 2-Aminothioazole-4-carboxylate a thiazolopyrimidinone derivative used as a modulator of NMDA receptor activity. Also a potential antiviral agent.

InChI:InChI=1/C10H14N2O4S/c1-10(2,3)16-9(14)12-8-11-6(5-17-8)7(13)15-4/h5H,1-4H3,(H,11,12,14)

Upstream product

• 118452-04-3 methyl 2-amino-1,3-thiazole-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 541-16-2 t-butyl malonate 

Downstream Products

• 876756-13-7 tert-butyl (4-(2-hydroxypropan-2-yl)thiazol-2-yl)carbamate 
• 876755-19-0 tert-butyl N-(4-propanoyl-1,3-thiazol-2-yl)carbamate 
• 947179-19-3 (4-Difluoromethylthiazol-2-yl)-carbamic acid tert-butyl ester 
• 494769-34-5 (4-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester 
• 494769-44-7 (4-hydroxymethylthiazol-2-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions. In this article, a series of 4,6-substituted-1H-indazole derivatives were synthesized and evaluated the inhibitory activities against IDO1 and TDO, as well as their structure-activity relationships (SARs). Among these, compound 35 displayed the most IDO1 inhibitory potency with an IC50 value of 0.74 μM in an enzymatic assay and 1.37 μM in HeLa cells. Quantitative analysis of the Western blot results indicated that 35 significantly decreased the INFγ-induced IDO1 expression in a concentration-dependent manner. In addition, 35 showed promising TDO inhibition with an IC50 value of 2.93 μM in the enzymatic assay and 7.54 μM in A172 cells. Moreover, compound 35 exhibited in vivo antitumor activity in the CT26 xenograft model. These findings suggest that 1H-indazole derivative 35 is a potent IDO1/TDO dual inhibitor, and has the potential to be developed for IDO1/TDO-related cancer treatment.

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

Substituted hydantoins

The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.